Exatecan

• UNSPSC Description:

  Exatecan (DX-8951) is a DNA topoisomerase I inhibitor, with an IC50 of 2.2 μM (0.975 μg/mL), and can be used in cancer research.

• Target Antigen:

  ADC Cytotoxin; Topoisomerase

• Type:

  Reference compound

• Related Pathways:

  Antibody-drug Conjugate/ADC Related;Cell Cycle/DNA Damage

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/exatecan.html

• Smiles:

  O=C1[C@](O)(CC)C2=C(CO1)C(N3CC4=C5C6=C(CC[C@@H]5N)C(C)=C(F)C=C6N=C4C3=C2)=O

• Molecular Weight:

  435.45

• References & Citations:

  [1]Mitsui I, et al. A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo. Jpn J Cancer Res. 1995 Aug;86(8):776-82.|[2]Sun FX, et al. Efficacy of camptothecin analog DX-8951f (Exatecan Mesylate) on human pancreatic cancer in an orthotopic metastatic model. Cancer Res. 2003 Jan 1;63(1):80-5.|[3]Joto N, et al. DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant. Int J Cancer. 1997 Aug 7;72(4):680-6.Mol Cancer Ther. 2023 Sep 5;22(9):1013-1027.|Patent. US20240191272A1.|Research Square Preprint. 2024 Nov 06.|Mol Pharm. 2022 Dec 2.|Nature. 2024 Apr;628(8007):416-423.|Patent. US20210009719A1.|Patent. US20220162323A1.|Patent. US20240190973A1.|Patent. US20240216525A1.|Patent. US20240374749A1.|Pharmaceuticals. 2021, 14(3), 247.

• Shipping Conditions:

  Blue Ice

• CAS Number:

  171335-80-1